NEW YORK (dpa-AFX Broker) - JPMorgan has given Sartorius shares "Positive Catalyst Watch" status, expecting positive news in the short term from the company's fiscal figures on Jan. 26. At the same time, however, analyst Richard Vosser lowered the price target of the preferred share from 570 to 550 euros in an outlook on the European pharmaceutical and biotech sector available Tuesday, but reiterated his rating of "Overweight." Vosser recommends quality stocks for 2023. He reduced his 2023 estimates for the sector only slightly, as it is likely to retain its high premium at least during the recession worries. On laboratory supplier Sartorius, Vosser wrote that it and subsidiary Stedim Biotech should continue to benefit from strong demand in the BPS (Bioprocess Solutions) business area. Thanks to a normalization of order intake, concerns about falling consensus estimates should also dissipate./ck/edh

Publication of the original study: 30.12.2022 / 21:34 / GMT

First release of the original study: 03.01.2023 / 00:15 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------